☰

Enrique Alvarez, MD, PhD - Publications

Affiliations: 
Neurology University of Colorado, Boulder, Boulder, CO, United States 
Area:
multiple sclerosis, biomarkers
Tree Info Grants Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis and Related Disorders. 68: 104143. PMID 36031693 DOI: 10.1016/j.msard.2022.104143  0.567
2022 Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, Häring DA, Hauser SL, Kappos L, et al. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology. 13: 852563. PMID 35432382 DOI: 10.3389/fimmu.2022.852563  0.502
2021 Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Multiple Sclerosis and Related Disorders. 55: 103170. PMID 34364034 DOI: 10.1016/j.msard.2021.103170  0.301
2020 Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 46: 102454. PMID 33045496 DOI: 10.1016/J.Msard.2020.102454  0.333
2020 Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology. PMID 32767538 DOI: 10.1002/Acn3.51111  0.414
2020 Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Annals of Clinical and Translational Neurology. PMID 32767531 DOI: 10.1002/Acn3.51136  0.357
2019 Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM. Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders. 38: 101508. PMID 31715503 DOI: 10.1016/J.Msard.2019.101508  0.365
2019 Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences. 407: 116498. PMID 31644992 DOI: 10.1016/J.Jns.2019.116498  0.387
2019 Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 36: 101402. PMID 31542710 DOI: 10.1016/J.Msard.2019.101402  0.355
2019 Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. Journal of Neuroimmunology. 332: 187-197. PMID 31077854 DOI: 10.1016/J.Jneuroim.2019.04.017  0.318
2019 Voge NV, Alvarez E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 7. PMID 30875812 DOI: 10.3390/Biomedicines7010020  0.423
2019 Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology. 6: 252-262. PMID 30847358 DOI: 10.1002/Acn3.700  0.416
2019 Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, Koulinska I, Fang F, Miller C, Chan A. Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes. Neurology and Therapy. PMID 30706431 DOI: 10.1007/S40120-019-0127-2  0.352
2019 Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. PMID 30635477 DOI: 10.1212/Wnl.0000000000006916  0.334
2018 Col NF, Solomon AJ, Springmann V, Ionete C, Alvarez E, Tierman B, Kutz C, Morales IB, Griffin C, Ngo LH, Jones DE, Phillips G, Hopson A, Pbert L. Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis. International Journal of Ms Care. 20: 260-267. PMID 30568563 DOI: 10.7224/1537-2073.2017-021  0.386
2018 Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Multiple Sclerosis and Related Disorders. 27: 383-390. PMID 30502644 DOI: 10.1016/J.Msard.2018.11.022  0.371
2018 Alvarez E, Mowry EM. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518794061. PMID 30346221 DOI: 10.1177/1352458518794061  0.342
2018 Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Multiple Sclerosis and Related Disorders. 27: 65-73. PMID 30342416 DOI: 10.1016/J.Msard.2018.09.037  0.624
2018 Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, ... ... Alvarez E, et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. The New England Journal of Medicine. 379: 846-855. PMID 30157388 DOI: 10.1056/Nejmoa1803583  0.717
2018 Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. Journal of the Neurological Sciences. 390: 89-93. PMID 29801915 DOI: 10.1016/J.Jns.2018.04.021  0.389
2018 Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. PMID 29749661 DOI: 10.1111/Jon.12518  0.658
2018 Almuklass AM, Davis L, Hamilton LD, Hebert JR, Alvarez E, Enoka RM. Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial. Neurorehabilitation and Neural Repair. 1545968317753681. PMID 29366377 DOI: 10.1177/1545968317753681  0.371
2017 Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. PMID 29093070 DOI: 10.1212/Wnl.0000000000004681  0.65
2017 Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 3: 2055217317725102. PMID 28839949 DOI: 10.1177/2055217317725102  0.305
2017 Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, et al. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurology(R) Neuroimmunology & Neuroinflammation. 4: e339. PMID 28382320 DOI: 10.1212/Nxi.0000000000000339  0.65
2016 Chen D, Ireland SJ, Remington G, Alvarez E, Racke MK, Greenberg B, Frohman EM, Monson NL. CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. Journal of Immunology (Baltimore, Md. : 1950). PMID 27798157 DOI: 10.4049/Jimmunol.1600782  0.327
2015 Alvarez E, Piccio L, Mikesell RJ, Trinkaus K, Parks BJ, Naismith RT, Cross AH. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 1: 2055217315623800. PMID 28607711 DOI: 10.1177/2055217315623800  0.713
2015 Patel KR, Luo J, Alvarez E, Piccio L, Schmidt RE, Yablonskiy DA, Cross AH. Detection of cortical lesions in multiple sclerosis: A new imaging approach. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 1: 2055217315606465. PMID 28607704 DOI: 10.1177/2055217315606465  0.693
2015 Seibert JB, Alvarez E. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology. 84: 861. PMID 25713115 DOI: 10.1212/01.Wnl.0000461938.49936.52  0.303
2013 Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1938-42. PMID 24277735 DOI: 10.1177/1352458513485654  0.721
2013 Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1204-8. PMID 23322500 DOI: 10.1177/1352458512473362  0.72
2012 Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Archives of Neurology. 69: 1482-7. PMID 22926050 DOI: 10.1001/Archneurol.2012.768  0.714
2011 Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Archives of Neurology. 68: 1156-64. PMID 21555606 DOI: 10.1001/Archneurol.2011.103  0.319
2011 Wu GF, Alvarez E. The immunopathophysiology of multiple sclerosis. Neurologic Clinics. 29: 257-78. PMID 21439440 DOI: 10.1016/J.Ncl.2010.12.009  0.418
2009 Klawiter EC, Alvarez E, Xu J, Paciorkowski AR, Zhu L, Parks BJ, Cross AH, Naismith RT. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology. 72: 1101-3. PMID 19307546 DOI: 10.1212/01.Wnl.0000345066.57745.50  0.726
Show low-probability matches.